Expanding Treatment Options for Type 2 Diabetes The Old and the New

American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2008;31(Suppl 1):S55-S60.

Pratley RE , Weyer C. The role of impaired early insulin secretion in the pathogenesis of type II diabetes mellitus. Diabetologia. 2001;44:929-945.

Dunning BE , Gerich JE The role of alpha-cell dysregulation in fasting and postprandial hyperglycemia in type 2 diabetes and therapeutic implications. Endocr Rev . 2007;28:253-283.

Mitrakou A. , Kelley D. , Veneman T. , et al. Contribution of abnormal muscle and liver glucose metabolism to postprandial hyperglycemia in NIDDM. Diabetes. 1990;39:1381-1390.

Nauck M. , Stöckmann F. , Ebert F. , Creutzfeldt W. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia. 1986;29:46-52.

Vilsboll T. , Holst JJ Incretins, insulin secretion and type 2 diabetes mellitus. Diabetologia. 2004;47:357-366.

Centers for Disease Control and Prevention. National diabetes fact sheet-United States, 2005. http://www.cdc.gov/diabetes/pubs/factsheet05.htm. Accessed September 2, 2008.

Stratton IM , Adler AI , Neil HA , et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study . BMJ. 2000;321:405-412.

Weyer C. , Bogardus C. , Mott DM , Pratley RE The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest . 1999;104:787-794.

Levy J. , Atkinson AB , Bell PM , et al. Beta-cell deterioration determines the onset and rate of progression of secondary dietary failure in type 2 diabetes mellitus: the 10-year follow-up of the Belfast Diet Study. Diabet Med. 1998 ;15:290-296.

Butler AE , Janson J. , Bonner-Weir S. , et al. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes. 2003;52:102-110.

Pratley RE Overview of glucagon-like peptide-1 analogs and dipeptidyl peptidase-4 inhibitors for type 2 diabetes. Medscape J Med. 2008;10:171.

Drucker DJ , Nauck MA The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006;368:1696-1705.

Brandt I. , Joossens J. , Chen X. , et al. Inhibition of dipeptidyl-peptidase IV catalyzed peptide truncation by vildagliptin ((2S)-{[(3-hydroxyadamantan-1-yl)amino]acetyl}-pyrrolidine-2-carbonitrile) . Biochem Pharmacol. 2005;70:134-143.

Byetta (exenatide injection) [prescribing information]. San Diego, CA: Amylin Pharmaceuticals Inc; June 2008.

Buse JB , Henry RR , Han J. , et al, for the Exenatide-113 Clinical Study Group. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care. 2004;27:2628-2635.

Kendall DM , Riddle MC , Rosenstock J. , et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea . Diabetes Care. 2005;28;1083-1091.

Amori RE , Lau J. , Pittas AG Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA. 2007;298:194-206.

DeFronzo RA , Ratner RE , Han J. , et al. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care. 2005;28:1092-1100.

Vilsboll T. , Zdravkovic M. , Le-Thi T. , et al. Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes. Diabetes Care. 2007;30:1608-1610.

Blonde L. , Rosenstock J. , Sesti G. , et al. Liraglutide: superior glycemic control vs exenatide when added to metformin and/or SU in type 2 diabetes. Presented at: Canadian Diabetes Association Congress; October 15-18, 2008; Montreal, Quebec. Abstract 107.

Januvia (sitagliptin) tablets [prescribing information]. Whitehouse Station, NJ: Merck & Co; July 2008.

Raz I. , Hanefeld M. , Xu L. , et al, for the Sitagliptin Study 023 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia . 2006;49:2564-2571.

Nauck MA , Meininger G. , Sheng D. , et al, for the Sitagliptin Study 024 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab. 2007;9:194-205.

Rosenstock J. , Baron MA , Dejager S. , et al. Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial. Diabetes Care. 2007;30:217-223.

Rosenstock J. , Baron MA , Camisasca RP , et al. Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes. Diabetes Obes Metab. 2007;9:175-185.

Garber AJ , Schweizer A. , Baron MA , et al. Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study. Diabetes Obes Metab . 2007;9:166-174.

Mari A. , Nielsen LL , Nanayakkara N. , et al. Mathematical modeling shows exenatide improved beta-cell function in patients with type 2 diabetes treated with metformin or metformin and a sulfonylurea. Horm Metab Res. 2006;38:838-844.

Ahrén B. , Pacini G. , Foley JE , Schweizer A. Improved meal-related beta-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year. Diabetes Care. 2005 ;28:1936-1940.

Chen J. , Couto FM , Minn AH , Shalev A. Exenatide inhibits beta-cell apoptosis by decreasing thioredoxin-interacting protein. Biochem Biophys Res Commun. 2006;346:1067-1074.

Xu G. , Stoffers DA , Habener JF , Bonner-Weir S. Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats . Diabetes. 1999;48:2270-2276.

Nathan DM , Buse JB , Davidson MB , et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. Diabetes Care. 2006;29: 1963-1972.

Kahn SE , Haffner SM , Heise MA , et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy [published correction appears in N Engl J Med. 2007;356:1387-1388] . N Engl J Med. 2006;355:2427-2443.

DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators , Gerstein HC , Yusuf S. , et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial [published correction appears in Lancet. 2006;368:1770]. Lancet. 2006;368:1096-1105.

Dormandy JA , Charbonnel B. , Eckland DJ , et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005;366:1279-1289.

Mateo JF , Gil-Guillen VF , Mateo E. , et al. Multifactorial approach and adherence to prescribed oral medications in patients with type 2 diabetes. Int J Clin Pract. 2006;60:422-428.

Nathan DM Initial management of glycemia in type 2 diabetes mellitus. N Engl J Med. 2002;347:1342-1349.

Riddle MC Glycemic management of type 2 diabetes: an emerging strategy with oral agents, insulins, and combinations. Endocrinol Metab Clin North Am . 2005;34:77-98.

Symlin (pramlintide acetate injection) [prescribing information] . San Diego, CA: Amylin Pharmaceuticals Inc; July 2008.

Brown JB , Nichols GA , Perry A. The burden of treatment failure in type 2 diabetes. Diabetes Care. 2004;27:1535-1540.

Nathan DM , Buse JB , Davidson MB , et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. Update regarding thiazolidinediones: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2008;31:173-175.

Banting lecture, ADA 68th Scientific Sessions, June 6-10, 2008, San Francisco, CA.